Compare SWVL & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWVL | HCWB |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United Arab Emirates | United States |
| Employees | 324 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 14.8M |
| IPO Year | N/A | 2021 |
| Metric | SWVL | HCWB |
|---|---|---|
| Price | $1.40 | $3.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 10.3K | ★ 62.8K |
| Earning Date | 04-20-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $0.25 |
| 52 Week High | $4.24 | $7.35 |
| Indicator | SWVL | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 51.51 |
| Support Level | $1.34 | $0.37 |
| Resistance Level | $1.59 | $4.00 |
| Average True Range (ATR) | 0.08 | 0.45 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 39.12 | 48.67 |
Swvl Holdings Corp is a technology-driven mobility company providing mass transit solutions. It currently has two offerings: business-to-consumer (B2C) and B2B (marketed as Swvl Business). The company's B2C business utilizes its platform to provide riders with a network of minibuses and other vehicles that operate on fixed and semi-fixed routes throughout and between different cities. Riders can book available seats on vehicles to commute within a city. The Swvl Business caters to corporate customers (as well as schools and municipalities), providing them with transportation solutions for their employees and students. This business also offers transportation management software to clients who operate their own fleet. Geographically, the company generates maximum revenue from Egypt.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.